REVIEW PAPER: Animals as Models of Age-Related Macular Degeneration: An Imperfect Measure of the Truth
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is a degenerative condition that begins in Bruch’s membrane and progresses to involve the retinal pigment epithelium and ultimately the overlying photoreceptors. The only required etiologic factor is age, and AMD is regarded as the leading cause of blindness in individuals older than 65 years. AMD results from variable contributions of age, environment, and genetic predisposition. Many loci are linked to AMD; in the majority of cases, the disease is associated with polymorphisms within these genes, rather than mutations that ablate gene function. The etiologic complexity of AMD is reflected by the paucity of animal models that entirely replicate the human disease. This review compares the salient anatomy of the primate and rodent retina, particularly in the light of AMD pathology. It next discusses prevailing hypotheses explaining how AMD may develop. These include the role of complement activation and macrophage chemotaxis in AMD, molecular mechanisms of choroidal neovascularization, and the roles of oxidative damage and lipid metabolism. Finally, the article gives an overview of spontaneous and induced nonhuman primate models and describes relevant mouse models in the context of each pathogenetic mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Self-citationThe Retinal Pigment Epithelium in Visual Function
Strauss, O. (2005) · Physiological Reviews · doi:10.1152/physrev.00021.2004 · Cited by 2,828
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449 · cited 2×
“The first complement associated gene polymorphism to be identified in AMD populations was the Y402H (tyrosine to histidine substitution at amino acid 402) variant of complement factor H (CFH).(28,44,47,62) Individuals homozygous for the risk-conferring 402H CFH variant have a five- to sevenfold greater risk of develop…”
BackgroundMethodComplement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424 · cited 2×
“The first complement associated gene polymorphism to be identified in AMD populations was the Y402H (tyrosine to histidine substitution at amino acid 402) variant of complement factor H (CFH).(28,44,47,62) Individuals homozygous for the risk-conferring 402H CFH variant have a five- to sevenfold greater risk of develop…”
BackgroundMethodHageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 2×
“Impaired CFH activity could conceivably result in overactivity of the alternate complement pathway, excessive complement deposition, and tissue injury in AMD.(44) This hypothesis has been difficult to prove.”
Allikmets, R., Singh, N., Sun, H., Shroyer, N. F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0397-236 · Cited by 1,435 · cited 1×
“Mutations in this gene result in an array of retinaldegenerative disorders, including AMD, and an early-onset form of macular disease known as Stargardt macular dystrophy.(1) Both conditions are characterized by excessive lipofuscin accumulation in the RPE.”
BackgroundAge-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379 · cited 1×
“Established epidemiologic risk factors include cigarette smoking, diet, female sex, Caucasian race, and a family history of AMD.(52,60,61) Because AMD is rare in individuals younger than 55 years, the only required risk factor is age, which implicates the multitude of cellular changes that accompany normal aging in th…”
BackgroundHageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265 · cited 3×
“With age, most people accumulate small, well-demarcated deposits of extracellular material beneath the RPE.(5,45) These are known as small, hard drusen and are not pathogenic.”
BackgroundA role for local inflammation in the formation of drusen in the aging eye
Anderson, D. H., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01624-0 · Cited by 1,087
Current concepts in the pathogenesis of age-related macular degeneration
Zarbin, M. A. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.598 · Cited by 1,006 · cited 2×
“RPE damage is an essential feature of AMD.(45,121) Drusen deposition is accompanied by accumulation of lipofuscin within RPE cells, as well as their progressive atrophy and degeneration.”
Background
Cited by
Animal models of age related macular degeneration
Pennesi, M. E., Neuringer, M., & Courtney, R. J. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.003 · Cited by 391
“These models will not be covered in this review and the reader is referred to several excellent reviews on these animals (Edwards and Malek, 2007; Rakoczy et al., 2006; Ramkumar et al., 2010; Zeiss, 2010).”
BackgroundResultMechanisms of age‐related macular degeneration and therapeutic opportunities
van Lookeren Campagne, M., LeCouter, J., Yaspan, B. L., & Ye, W. (2014) · The Journal of Pathology · doi:10.1002/path.4266 · Cited by 382
Microglia in Retinal Degeneration
Rashid, K., Akhtar-Schaefer, I., & Langmann, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01975 · Cited by 355
(2012) · PubMed Central · Cited by 150
A local complement response by RPE causes early-stage macular degeneration
Fernandez-Godino, R., Garland, D. L., & Pierce, E. A. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv287 · Cited by 73
“The Efemp1 RPE culture system recapitulates the formation of sub-RPE deposits in vitro in only 2 weeks, compared with months in Efemp1 and other gene-targeted mice (43,56).”
ResultLyzogubov, V. V., Bora, P. S., Wu, X., Horn, L. E., de Roque, R., Rudolf, X. V., Atkinson, J. P., & Bora, N. S. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.03.021 · Cited by 45
Importance of nonhuman primates as a model system for gene therapy development in ophthalmology
Wozar, F., Seitz, I., Reichel, F., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1777-5033 · Cited by 6
Metadata
- Authors
- Zeiss, C. J.
- Venue
- Veterinary Pathology
- Publisher
- SAGE Publications
- Published
- 2010-04-09
- Volume
- 47
- Issue
- 3
- Pages
- 396-413
- ISSN
- 0300-9858 (ISSN-L)
- 1544-2217
- OpenAlex
- W2166908058
- Cited by
- 102
- References
- 45
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.